Literature DB >> 20124546

The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe?

Tobias E Larsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20124546     DOI： 10.1093/ndt/gfp784

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  17 in total

1.  Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure.

Authors:  Farah N Ali; Bonita Falkner; Samuel S Gidding; Heather E Price; Scott W Keith; Craig B Langman
Journal:  J Pediatr       Date:  2014-07-22       Impact factor: 4.406

2.  FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.

Authors:  Sigrid Lundberg; Abdul Rashid Qureshi; Sara Olivecrona; Iva Gunnarsson; Stefan H Jacobson; Tobias E Larsson
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-01       Impact factor: 8.237

3.  Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.

Authors:  Emilio González-Parra; Álvaro Aceña; Óscar Lorenzo; Nieves Tarín; María Luisa González-Casaus; Carmen Cristóbal; Ana Huelmos; Ignacio Mahíllo-Fernández; Ana María Pello; Rocío Carda; Ignacio Hernández-González; Joaquín Alonso; Fernando Rodríguez-Artalejo; Lorenzo López-Bescós; Alberto Ortiz; Jesús Egido; José Tuñón
Journal:  J Bone Miner Metab       Date:  2015-08-23       Impact factor: 2.626

Review 4.  Familial tumoral calcinosis: a valuable vehicle for discovery.

Authors:  Orson W Moe
Journal:  Nephrol Dial Transplant       Date:  2014-08-21       Impact factor: 5.992

Review 5.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

6.  Hemodialysis is associated with higher serum FGF23 level when compared with peritoneal dialysis.

Authors:  Shuhong Bi; Yaoxian Liang; Litao Cheng; Yue Wang; Tao Wang; Qinfeng Han; Aihua Zhang
Journal:  Int Urol Nephrol       Date:  2017-04-28       Impact factor: 2.370

7.  Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.

Authors:  Jacob A Udell; David A Morrow; Petr Jarolim; Sarah Sloan; Elaine B Hoffman; Thomas F O'Donnell; Amit N Vora; Torbjørn Omland; Scott D Solomon; Marc A Pfeffer; Eugene Braunwald; Marc S Sabatine
Journal:  J Am Coll Cardiol       Date:  2014-04-09       Impact factor: 24.094

8.  FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock.

Authors:  Janine Pöss; Felix Mahfoud; Sarah Seiler; Gunnar H Heine; Danilo Fliser; Michael Böhm; Andreas Link
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09

9.  Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet.

Authors:  Wei Ling Lau; Elizabeth M Leaf; Ming Chang Hu; Marc M Takeno; Makoto Kuro-o; Orson W Moe; Cecilia M Giachelli
Journal:  Kidney Int       Date:  2012-08-29       Impact factor: 10.612

10.  Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.

Authors:  Julia J Scialla; Wei Ling Lau; Muredach P Reilly; Tamara Isakova; Hsueh-Ying Yang; Matthew H Crouthamel; Nicholas W Chavkin; Mahboob Rahman; Patricia Wahl; Ansel P Amaral; Takayuki Hamano; Stephen R Master; Lisa Nessel; Boyang Chai; Dawei Xie; Radhakrishna R Kallem; Jing Chen; James P Lash; John W Kusek; Matthew J Budoff; Cecilia M Giachelli; Myles Wolf
Journal:  Kidney Int       Date:  2013-02-06       Impact factor: 10.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.